U.S. FDA authorizes Moderna, Pfizer updated COVID boosters for 6 months old

,
FDA

U.S. FDA authorizes Moderna, Pfizer updated COVID boosters for 6 months old

Dec 8 (Reuters) – The U.S. Food and Drug Administration on Thursday authorized updated COVID-19 booster shots from Moderna (MRNA.O) and Pfizer (PFE.N) and its partner BioNTech (22UAy.DE) for children as young as 6 months of age.

The amended authorizations allow use of Moderna’s bivalent shot in children 6 months through 5 years of age, while the Pfizer/BioNTech vaccine can be given to those aged 6 months through 4 years.

Pfizer’s shot can be administered as the third shot for those eligible and have not completed their primary vaccination series, the agency added.

Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

/by
You might also like
ASCO, ACCC join forces to increase diversity in cancer clinical trials
FDADoctors urge U.S. FDA to add miscarriage management to abortion pill label
FDAFDA flags issues at Coherus partner’s China plant for cancer drug
AstraZeneca returns to FibroGen the rights to roxadustat in U.S., other territories
Pharma sustainabilityTop pharma companies 2023: A satisfactory year
Pfizer BioNTechPfizer, BioNTech start COVID-flu combination vaccine study
GSK logoU.S. FDA extends review for GSK-owned Sierra’s blood cancer therapy
Outlook Therapeutics logoOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration